Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

Enlivex Therapeutics Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NESS-ZIONA, ISRAEL, OCT. 28, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD. (NASDAQ: ENLV, THE COMPANY), A CLINICAL-STAGE MACROPHAGE REPROGRAMMING IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED THAT IT WILL PRESENT A LATE-BREAKING POSTER ABSTRACT AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025, TAKING PLACE OCTOBER 2429 AT MCCORMICK PLACE CONVENTION CENTER IN CHICAGO, ILLINOIS.

ENLIVEX THERAPEUTICS TO PRESENT PHASE IIA 3-MONTH DATA OF ALLOCETRA IN PATIENTS WITH MODERATE-TO-SEVERE KNEE OSTEOARTHRITIS AT THE ACR CONVERGENCE 2025

NES-ZIONA, ISRAEL, SEPT. 29, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD. (NASDAQ: ENLV, THE COMPANY), A CLINICAL-STAGE MACROPHAGE REPROGRAMMING IMMUNOTHERAPY COMPANY, WILL PARTICIPATE IN A LIVE INVESTOR WEBINAR, ADVANCING INFLAMMATORY DISEASE TREATMENT: INSIGHTS & BREAKTHROUGHS FROM ENLIVEX'S KNEE OSTEOARTHRITIS PROGRAM, HOSTED BY D. BORAL CAPITAL ON SEPTEMBER 30, 2025, AT 10:00 AM EASTERN TIME. THE DISCUSSION WILL BRING TOGETHER LEADING KEY OPINION LEADERS (KOLS) IN MUSCULOSKELETAL DISEASE, ALONGSIDE ENLIVEX'S VICE CHAIRMAN AND D. BORAL'S RESEARCH DIRECTOR.THE SEPTEMBER 30 KOL WEBINAR WILL EXPLORE RECENT BREAKTHROUGHS IN TREATMENT APPROACHES DISCUSSING THE POSITIVE PHASE IIA TOPLINE DATA FROM ENLIVEX'S ALLOCETRA PROGRAM IN MODERATE-TO-SEVERE KNEE OSTEOARTHRITIS (KOA) PATIENTS. DATA DEMONSTRATED CLINICALLY MEANINGFUL AND HIGHLY STATISTICALLY SIGNIFICANT REDUCTION IN PAIN AND IMPROVEMENTS IN FUNCTION IN IDIOPATHIC, AGE-RELATED KNEE OSTEOARTHRITIS PATIENTS, A LARGE, UNDERSERVED POPULATION.

Enlivex Therapeutics Ltd.

ENLV

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Enlivex Therapeutics Ltd.

ENLV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ENLV